Anti-Inflammatory Interventions in End-stage Kidney Disease: A Randomized, Double-Blinded, Controlled and Crossover Clinical Trial on the Use of Pravastatin in Continuous Ambulatory Peritoneal Dialysis-Reference-Cited by-同舟云学术

Anti-Inflammatory Interventions in End-stage Kidney Disease: A Randomized, Double-Blinded, Controlled and Crossover Clinical Trial on the Use of Pravastatin in Continuous Ambulatory Peritoneal Dialysis

Published:2013-11 Issue:8 Volume:44 Page:633-637
ISSN:0188-4409
Container-title:Archives of Medical Research
language:en
Short-container-title:Archives of Medical Research

Author:

Cueto-Manzano Alfonso M.,Ángel-Zúñiga Juan R.,Ornelas-Carrillo Gabina,Rojas-Campos Enrique,Martínez-Ramírez Héctor R.,Cortés-Sanabria Laura

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?;Arici;Kidney Int,2001

2. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome—the heart of the matter;Pecoits-Filho;Nephrol Dial Transplant,2002

3. Inflammation and cardiovascular risk in dialysis patients;Wanner;Kidney Int,2002

4. The United States Renal Data System. Annual Data Report. 2012. http://www.usrds.org (15 July 2013 date last accessed).

5. Inflammation in renal disease;Vidt;Am J Cardiol,2006

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pravastatin for lowering lipids;Cochrane Database of Systematic Reviews;2023-09-18

2. From MIA to FIFA: The vicious matrix of frailty, inflammation, fluid overload and atherosclerosis in peritoneal dialysis;Nephrology;2023-02-25

3. Clinical trials and future perspectives of antiinflammatory agents;Recent Developments in Anti-Inflammatory Therapy;2023

4. Antidyslipidemia Pharmacotherapy in Chronic Kidney Disease: A Systematic Review and Bayesian Network Meta-Analysis;Pharmaceutics;2022-12-20

5. Improvement of clinical outcomes in patients undergoing peritoneal dialysis using hydroxymethylglutaryl-CoA reductase inhibitors: A systematic review and meta-analysis;Journal of the Chinese Medical Association;2022-11-04